Multiple Sclerosis 'immune Exchange' Between Brain and Blood Is UncoveredScience Daily (press release)These trials used Rituximab and Ocrelizumab, both of which target a molecule called CD20 found on the surface of B cells. The new work suggest…
Musculoskeletal Network Launches Special Coverage of FDA Biosimilars PolicyMelodika.net (press release)Many newer "biological" drugs currently approved for these disorders, such as adalimumab (Humira) and rituximab (Rituxan), are identical to…
Drug Combo Offers Long-Term Benefits in SLEMedPage TodayWASHINGTON — An 18-month treatment with the combination of rituximab and cyclophosphamide (Cytoxan) stopped progression of systemic lupus erythematosus (SLE) for at least 3 years, researchers her…
Immunotherapeutic Approaches Have the Potential to Brighten the Future Not …Cancer NetworkAs critically discussed by the authors, a multitude of previous trials and currently available treatment regimens, including rituximab-based chemo-immunotherapy…
Is the show over for CYC in ANCA-associated vasculitis?Rheumatology UpdateWASHINGTON: Cyclophosphamide continues to have a role in ANCA-associated vasculitis but rituximab can be considered a valid option for newly diagnosed patients with severe diseas…
Rituxan Turns in Good Safety Profile in RAMedPage TodayWASHINGTON — Serious infectious events associated with rituximab (Rituxan) remain consistently low in rheumatoid arthritis (RA) patients for nearly a decade after first treatment, researchers said…
9.5-Year Follow-Up on Effects of Rituximab in RA PatientsProHealthThe drug rituximab is used in combination with methotrexate to control autoimmune damage to RA patients' joints by reducing levels of a specific immune B-cell that attacks them. The …
Halozyme Reports Third Quarter 2012 Financial ResultsSacramento Bee"We are pleased with the clinical data from the subcutaneous MabThera (rituximab) trials which should enable filing of the marketing application in Europe later this year," sa…
TG Therapeutics, Inc. Announces Third Quarter 2012 Financial Results and …Equities.comThe following abstracts were accepted for presentation: Ublituximab (TG-1101), an Optimized Anti-CD20 Monoclonal Antibody, Demonstrates Greater NK-Mediated ADCC Tha…
News briefs: Rituximab biosimilar; Watson to change name; Baxter Brazil plans …The Pharma LetterThe Sandoz follicular lymphoma Phase III clinical trial for biosimilar monoclonal antibody rituximab, a biosimilar of Roche's Rituxan/MabThera (which …